<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:684c74b7-17a4-49da-b1bb-c58f69c27778,g:fc07c246-7cd6-463d-bc54-48235aecf74d,d:5710281f0c0c4252a5caadff0b4289cb--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdxg-20210913</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl80L2ZyYWc6MzM2NzU1ZDRjZjA0NDQ2YWExNjU4ZGQ4MmI1ZmY5ZTEvdGFibGU6NzBiNWFkZjM0Y2IwNGUwNjkxNTQ5Zjg0MDQwYWQzNTMvdGFibGVyYW5nZTo3MGI1YWRmMzRjYjA0ZTA2OTE1NDlmODQwNDBhZDM1M18yLTEtMS0xLTU5Nzk_1cd03bd9-dd84-4837-a978-0d769a4f41de">0001376339</ix:nonNumeric><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl80L2ZyYWc6MzM2NzU1ZDRjZjA0NDQ2YWExNjU4ZGQ4MmI1ZmY5ZTEvdGFibGU6NzBiNWFkZjM0Y2IwNGUwNjkxNTQ5Zjg0MDQwYWQzNTMvdGFibGVyYW5nZTo3MGI1YWRmMzRjYjA0ZTA2OTE1NDlmODQwNDBhZDM1M180LTEtMS0xLTU5Nzk_226ff84a-c7fe-4139-bd7b-a80387e19f4c">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdxg-20210913.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-13</xbrli:startDate><xbrli:endDate>2021-09-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5710281f0c0c4252a5caadff0b4289cb_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDcz_922b16f0-62a3-43fb-b75f-ce2790fdd77a">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl8yNjY_67a6d050-9aed-4dd6-a1ba-184aa82e4652">September 13, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDc4_47741437-53d0-4853-b7de-d5c642ec446b">MIMEDX GROUP, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6NzM4YjFkNGJjOTc4NDNiMWE0ZTQyOGQxOGExNWVhY2UvdGFibGVyYW5nZTo3MzhiMWQ0YmM5Nzg0M2IxYTRlNDI4ZDE4YTE1ZWFjZV8wLTAtMS0xLTU5Nzk_0608b6db-c19a-425b-af49-34f522f69cd9">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6NzM4YjFkNGJjOTc4NDNiMWE0ZTQyOGQxOGExNWVhY2UvdGFibGVyYW5nZTo3MzhiMWQ0YmM5Nzg0M2IxYTRlNDI4ZDE4YTE1ZWFjZV8wLTItMS0xLTU5Nzk_f8daa35a-4f5d-404f-86be-1000290a97ca">001-35887</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6NzM4YjFkNGJjOTc4NDNiMWE0ZTQyOGQxOGExNWVhY2UvdGFibGVyYW5nZTo3MzhiMWQ0YmM5Nzg0M2IxYTRlNDI4ZDE4YTE1ZWFjZV8wLTQtMS0xLTU5Nzk_08f5d61b-066d-40be-aa81-d9cb03aaaf52">26-2792552</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDc0_e18c34b5-7b3c-4f09-bfc0-3cf279281ce7">1775 West Oak Commons Ct., NE</ix:nonNumeric>, <ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDc5_ce4f9c93-91b2-4749-88bd-23bdc31f8b58">Marietta</ix:nonNumeric> <ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDgw_5e892382-dde0-444d-bbc1-a7a7b45db318">GA</ix:nonNumeric> <ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDc1_8af722ce-9bd6-4324-8bc6-fe36e0d3224a">30062</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDc2_e1b5c300-8351-4e51-a0e3-f67d1c517192">770</ix:nonNumeric>) <ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDgx_8d05e18a-300d-47a7-8773-e9a2b6310139">651-9100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:0.1%"></td><td style="width:2.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6YmVjZGUxNDVjYjIwNDM3ZWIzNjllYjI4YjYxYzNhZGYvdGFibGVyYW5nZTpiZWNkZTE0NWNiMjA0MzdlYjM2OWViMjhiNjFjM2FkZl8wLTAtMS0xLTU5Nzk_fa063aff-9dee-447c-9097-5c5ae82f8873">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6YmVjZGUxNDVjYjIwNDM3ZWIzNjllYjI4YjYxYzNhZGYvdGFibGVyYW5nZTpiZWNkZTE0NWNiMjA0MzdlYjM2OWViMjhiNjFjM2FkZl8xLTAtMS0xLTU5Nzk_8cf0dabd-507c-4c06-8199-2e3bf643a54f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6YmVjZGUxNDVjYjIwNDM3ZWIzNjllYjI4YjYxYzNhZGYvdGFibGVyYW5nZTpiZWNkZTE0NWNiMjA0MzdlYjM2OWViMjhiNjFjM2FkZl8yLTAtMS0xLTU5Nzk_d96817a9-28b4-48cd-ac71-dfc63b6ded44">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6YmVjZGUxNDVjYjIwNDM3ZWIzNjllYjI4YjYxYzNhZGYvdGFibGVyYW5nZTpiZWNkZTE0NWNiMjA0MzdlYjM2OWViMjhiNjFjM2FkZl8zLTAtMS0xLTU5Nzk_d0c26537-6ae1-42c6-baf1-394d5a18f78d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:27.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6M2UxNGVjNTI0ZDlhNDIyOGJiMzZiOWQ1N2M5MTIyYWEvdGFibGVyYW5nZTozZTE0ZWM1MjRkOWE0MjI4YmIzNmI5ZDU3YzkxMjJhYV8xLTAtMS0xLTU5Nzk_1baa5cdd-213c-4909-9765-89c4428623d5">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6M2UxNGVjNTI0ZDlhNDIyOGJiMzZiOWQ1N2M5MTIyYWEvdGFibGVyYW5nZTozZTE0ZWM1MjRkOWE0MjI4YmIzNmI5ZDU3YzkxMjJhYV8xLTItMS0xLTU5Nzk_b0243444-fe34-4886-ba75-bd4a22ad65ec">MDXG</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGFibGU6M2UxNGVjNTI0ZDlhNDIyOGJiMzZiOWQ1N2M5MTIyYWEvdGFibGVyYW5nZTozZTE0ZWM1MjRkOWE0MjI4YmIzNmI5ZDU3YzkxMjJhYV8xLTQtMS0xLTU5Nzk_add54e29-b86d-4c5a-b2e9-67e266f79bba">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i415ba77da26241b0a95b7328cdf329ba_D20210913-20210913" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU3MTAyODFmMGMwYzQyNTJhNWNhYWRmZjBiNDI4OWNiL3NlYzo1NzEwMjgxZjBjMGM0MjUyYTVjYWFkZmYwYjQyODljYl8xL2ZyYWc6NzVhN2QyNzU1ZjQ1NDk1Zjg3YjU0MDc3MGVmOGRmMjYvdGV4dHJlZ2lvbjo3NWE3ZDI3NTVmNDU0OTVmODdiNTQwNzcwZWY4ZGYyNl82MDc3_0001617a-ff3e-4b3b-a53d-d6cc5ef35215">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Important Cautionary Statement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This report includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: (i) future sales or sales growth; (ii) the Company&#8217;s plans to review and conduct additional analyses of the clinical trial data from its plantar fasciitis, Achilles tendonitis, and knee osteoarthritis clinical trials and expectations regarding the results of such analyses, including expectations regarding safety and efficacy, and the value of safety data from the trials and these analyses; the Company&#8217;s expectations regarding its mdHACM product&#8217;s potential use as a safe and effective treatment option, and that it may be an effective treatment for persons battling inflammatory conditions; the Company&#8217;s plans for completing 12-month safety visit follow-up and its timing; plans for meetings with the FDA, and planned biologics license application (BLA) submissions to the FDA, and their timing; plans for future clinical trials, including the Company&#8217;s decision to pursue or not pursue, and their timing; (iii) estimates of potential market size for the Company&#8217;s future products; (iv) plans for expansion outside of the U.S., or the potential to expand the Company&#8217;s portfolio of products through licensing transactions or additional clinical research; the effectiveness of amniotic tissue as a therapy for any particular indication or condition; (v) expected spending on research and development in 2021; (vi) the Company&#8217;s long-term strategy for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth; </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(ii) the results of a clinical trial or trials may not demonstrate that the product is safe or effective, or may have little or no statistical value; the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public announcements; the timing of any meeting with the FDA depends on many factors and is outside of the Company&#8217;s control, and the results from any meeting are uncertain; a BLA submission requires a number of prerequisites, including favorable study results and statistical support, and completion of a satisfactory FDA inspection of the Company&#8217;s manufacturing facility or facilities; plans for future clinical trials depend on the results of pending clinical trials, discussion with the FDA, and other factors; and conducting clinical trials is a time-consuming, expensive, and uncertain process; (iii) the future market for the Company&#8217;s products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company&#8217;s products, market acceptance of the Company&#8217;s products, and adequate reimbursement for such therapies; (iv) the process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; (v) the results of a clinical trial or trials may have little or no statistical value, or may fail to demonstrate that the product is safe or effective; and (vi) expected spending can depend in part on the results of pending clinical trials;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 7.01 Regulation FD.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, MIMEDX Group, Inc. (the &#8220;Company&#8221;), issued a press release announcing the top-line results from two late-stage musculoskeletal clinical trials of the Company&#8217;s micronized dehydrated Human Amnion Chorion Membrane (mdHACM): a Phase 2B clinical trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein for reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 13, 2021, Timothy R. Wright, MIMEDX Chief Executive Officer, Peter M. Carlson, MIMEDX Chief Financial Officer, and Robert B. Stein, M.D. Ph.D, MIMEDX Executive Vice President, Research and Development are expected to present at the H.C. Wainwright 23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Annual Global Investment Conference</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> beginning at 9:00 AM Eastern time. A copy of the presentation materials they will use are attached hereto as Exhibit 99.2 and are incorporated herein for reference. The presentation materials shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section and shall only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrialre.htm">Press Release </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrialre.htm">Sep</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrialre.htm">tember</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrialre.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrialre.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrialre.htm">3, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210913reclinicaltrial.htm">Slide Presentation dated September 13, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MIMEDX GROUP, INC.</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: September 13, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter M. Carlson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson<br/>Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "mdxg-20210913.htm", "description": "8-K", "secsgml_size_bytes": 41666}]
{"company-data": {"conformed-name": "MIMEDX GROUP, INC.", "cik": "0001376339", "assigned-sic": "3841", "irs-number": "262792552", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35887", "film-number": "211248555"}, "business-address": {"street1": "1775 W OAK COMMONS COURT, NE", "city": "MARIETTA", "state": "GA", "zip": "30062", "phone": "(770) 651-9100"}, "mail-address": {"street1": "1775 W OAK COMMONS COURT, NE", "city": "MARIETTA", "state": "GA", "zip": "30062"}, "former-company": {"former-conformed-name": "Alynx, Co.", "date-changed": "20060922"}}
mdxg-20210913
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM
8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
September 13, 2021
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
Florida
001-35887
26-2792552
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
1775 West Oak Commons Ct., NE
,
Marietta
GA
30062
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (
770
)
651-9100
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.001 par value per share
MDXG
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Important Cautionary Statement
This report includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: (i) future sales or sales growth; (ii) the Company's plans to review and conduct additional analyses of the clinical trial data from its plantar fasciitis, Achilles tendonitis, and knee osteoarthritis clinical trials and expectations regarding the results of such analyses, including expectations regarding safety and efficacy, and the value of safety data from the trials and these analyses; the Company's expectations regarding its mdHACM product's potential use as a safe and effective treatment option, and that it may be an effective treatment for persons battling inflammatory conditions; the Company's plans for completing 12-month safety visit follow-up and its timing; plans for meetings with the FDA, and planned biologics license application (BLA) submissions to the FDA, and their timing; plans for future clinical trials, including the Company's decision to pursue or not pursue, and their timing; (iii) estimates of potential market size for the Company's future products; (iv) plans for expansion outside of the U.S., or the potential to expand the Company's portfolio of products through licensing transactions or additional clinical research; the effectiveness of amniotic tissue as a therapy for any particular indication or condition; (v) expected spending on research and development in 2021; (vi) the Company's long-term strategy for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth;
Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i)
future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors;
(ii) the results of a clinical trial or trials may not demonstrate that the product is safe or effective, or may have little or no statistical value; the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public announcements; the timing of any meeting with the FDA depends on many factors and is outside of the Company's control, and the results from any meeting are uncertain; a BLA submission requires a number of prerequisites, including favorable study results and statistical support, and completion of a satisfactory FDA inspection of the Company's manufacturing facility or facilities; plans for future clinical trials depend on the results of pending clinical trials, discussion with the FDA, and other factors; and conducting clinical trials is a time-consuming, expensive, and uncertain process; (iii) the future market for the Company's products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company's products, market acceptance of the Company's products, and adequate reimbursement for such therapies; (iv) the process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; (v) the results of a clinical trial or trials may have little or no statistical value, or may fail to demonstrate that the product is safe or effective; and (vi) expected spending can depend in part on the results of pending clinical trials;
The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.
Item 7.01 Regulation FD.
On September 13, 2021, MIMEDX Group, Inc. (the "Company"), issued a press release announcing the top-line results from two late-stage musculoskeletal clinical trials of the Company's micronized dehydrated Human Amnion Chorion Membrane (mdHACM): a Phase 2B clinical trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein for reference.
On September 13, 2021, Timothy R. Wright, MIMEDX Chief Executive Officer, Peter M. Carlson, MIMEDX Chief Financial Officer, and Robert B. Stein, M.D. Ph.D, MIMEDX Executive Vice President, Research and Development are expected to present at the H.C. Wainwright 23
rd
Annual Global Investment Conference
beginning at 9:00 AM Eastern time. A copy of the presentation materials they will use are attached hereto as Exhibit 99.2 and are incorporated herein for reference. The presentation materials shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section and shall only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description of Exhibit
99.1
Press Release
Sep
tember
1
3, 2021.
99.2
Slide Presentation dated September 13, 2021.
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MIMEDX GROUP, INC.
Date: September 13, 2021
By:
/s/ Peter M. Carlson
Peter M. Carlson
Chief Financial Officer